Previous 10 | Next 10 |
ADX71149 Phase 2 e pilepsy c linical s tudy Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendation Indivior GABAB PAM collaboration extended to June 2024 with CHF 2.7 million of committe...
Geneva, Switzerland, August 3 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on Augu...
2023-08-03 13:22:27 ET Clinical-stage pharmaceutical company Addex Therapeutics ( NASDAQ: ADXN ) said that its agreement related to the discovery of drug candidates for treating substance use disorder stands extended until June 30. Addex also said that under the extended agree...
Discovery c ollaboration on track to deliver clinical candidate s for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 3 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), ...
Data published in Neuropharmacology shows mGlu2 PAM s attenuate oxycodone use and potential as a novel treatment f or opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 2 4 ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 1 5 , 202 3 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and developme...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 1 , 202 3 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (...
2023-05-18 02:59:43 ET Clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, Addex Therapeutics ( NASDAQ: ADXN ) received Nasdaq notice that, for the last thirty consecutive business days, the bid price for the c...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 1 8 , 202 2 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development ...
2023-05-12 18:39:02 ET Addex Therapeutics Ltd. (ADXN) Q1 2023 Earnings Conference Call May 11, 2023 10:00 AM ET Company Participants Timothy Dyer – Chief Executive Officer Robert Lütjens – Head of Discovery-Biology Conference Call Participant...
News, Short Squeeze, Breakout and More Instantly...
Addex Therapeutics Ltd Company Name:
ADXN Stock Symbol:
NASDAQ Market:
Addex Therapeutics Ltd Website:
2024-07-19 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...